Efficacy and Safety of UV1 Vaccination in Combination With Nivolumab and Ipilimumab as First Line Treatment of Patients With Unresectable or Metastatic Melanoma (INITIUM Study)
Latest Information Update: 20 Jan 2025
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Sargramostim (Primary) ; UV 1 (Primary)
- Indications Malignant melanoma
- Focus Proof of concept; Therapeutic Use
- Acronyms INITIUM
- Sponsors Ultimovacs AS
Most Recent Events
- 21 Aug 2024 According to an Ultimovacs AS media release, the results of INITIUM supplementary study are expected to be submitted for publication in a peer-reviewed medical journal by the end of this year.
- 04 Jun 2024 Results(n=156) , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 24 Apr 2024 According to an Ultimovacs AS media release, the trial was conducted at 39 hospitals across the U.S., U.K., Belgium, and Norway, and 156 patients were enrolled between June 2020 and July 2022.